Diabetes Care & Metabolic Syndrome

As per IDF, in 2019 approximately 463 million adults (20-79 years) were living with diabetes; by 2045 this will rise to 700 million.
The proportion of people with type 2 diabetes is increasing in most countries.

People with diabetes are two to three times more likely to have cardiovascular disease than people without diabetes.

Diabetes, hypertension, or a combination of both, cause 80% of end-stage renal disease globally.

Diabetes-care & Metabolic Syndrome (DMS) portfolio was launched in 2017, with the objective of targeting the fast-growing Diabetes market in India.
BioGenomics Ltd is the only company to offer the entire range of Insulin Analogues and oral anti-diabetic drugs. DMS follows a scientific therapeutic approach by providing patients with a comprehensive range of:
  • Oral Anti Diabetic drugs
  • Products for Managing diabetic complications (Diabetic Neuropathy, Diabetic Foot Ulcers)
  • Metabolic syndrome (Lipids, Obesity)
  • Nutritional supplements.
DMS aims to be a niche player in the Diabetes and Metabolic syndrome space and to service patients with its comprehensive range of Innovative & differentiated brands.
Diabetes Care Portfolio
Metabolic Syndrome Portfolio